These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25637604)

  • 1. A G protein-coupled receptor dimer imaging assay reveals selectively modified pharmacology of neuropeptide Y Y1/Y5 receptor heterodimers.
    Kilpatrick LE; Humphrys LJ; Holliday ND
    Mol Pharmacol; 2015 Apr; 87(4):718-32. PubMed ID: 25637604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
    Gehlert DR; Schober DA; Morin M; Berglund MM
    Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
    Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
    Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
    Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
    J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
    Dumont Y; Cadieux A; Doods H; Fournier A; Quirion R
    Can J Physiol Pharmacol; 2000 Feb; 78(2):116-25. PubMed ID: 10737674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of G protein and phospholipase C-coupled agonist binding to the Y1 neuropeptide Y receptor in rat brain: sensitivity to G protein activators and inhibitors and to inhibitors of phospholipase C.
    Parker SL; Parker MS; Sweatman T; Crowley WR
    J Pharmacol Exp Ther; 1998 Jul; 286(1):382-91. PubMed ID: 9655883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
    Henry M; Ghibaudi L; Gao J; Hwa JJ
    Obes Res; 2005 Jan; 13(1):36-47. PubMed ID: 15761161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of neuropeptide Y receptor association with beta-arrestin2 measured by bimolecular fluorescence complementation.
    Kilpatrick LE; Briddon SJ; Hill SJ; Holliday ND
    Br J Pharmacol; 2010 Jun; 160(4):892-906. PubMed ID: 20438572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased brain neuropeptide Y1 and Y2 receptor binding in NPY knock out mice does not result in increased receptor function.
    Gehlert DR; Shaw JL
    Peptides; 2007 Feb; 28(2):241-9. PubMed ID: 17208335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of cloned chicken neuropeptide Y receptors Y1 and Y5.
    Holmberg SK; Mikko S; Boswell T; Zoorob R; Larhammar D
    J Neurochem; 2002 May; 81(3):462-71. PubMed ID: 12065655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors.
    Morris MJ; Gannan E; Stroud LM; Beck-Sickinger AG; O'Brien TJ
    Eur J Neurosci; 2007 Feb; 25(4):1136-43. PubMed ID: 17331209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning and characterization of rabbit neuropeptide Y receptor subtypes.
    Umeda T; Kanatani A; Iwaasa H
    Peptides; 2009 Aug; 30(8):1441-7. PubMed ID: 19481128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system.
    Pons J; Kitlinska J; Ji H; Lee EW; Zukowska Z
    Can J Physiol Pharmacol; 2003 Feb; 81(2):177-85. PubMed ID: 12710532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms.
    Gao J; Ghibaudi L; Hwa JJ
    Am J Physiol Endocrinol Metab; 2004 Oct; 287(4):E706-11. PubMed ID: 15187000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains.
    Dumont Y; Jacques D; Bouchard P; Quirion R
    J Comp Neurol; 1998 Dec; 402(3):372-84. PubMed ID: 9853905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging and long-term caloric restriction regulate neuropeptide Y receptor subtype densities in the rat brain.
    Veyrat-Durebex C; Quirion R; Ferland G; Dumont Y; Gaudreau P
    Neuropeptides; 2013 Jun; 47(3):163-9. PubMed ID: 23410741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation.
    Sørensen G; Lindberg C; Wörtwein G; Bolwig TG; Woldbye DP
    J Neurosci Res; 2004 Sep; 77(5):723-9. PubMed ID: 15352219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors.
    Dautzenberg FM; Neysari S
    Pharmacology; 2005 Dec; 75(1):21-9. PubMed ID: 15908753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
    Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H
    J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward Labeled Argininamide-Type NPY Y1 Receptor Antagonists: Identification of a Favorable Propionylation Site in BIBO3304.
    Keller M; Schindler L; Bernhardt G; Buschauer A
    Arch Pharm (Weinheim); 2015 Jun; 348(6):390-8. PubMed ID: 25884646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.